{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:28:12Z","timestamp":1793104092326,"version":"4.5.0"},"reference-count":270,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer\u00a0treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed\/refractory (R\/R) B cell malignancies. At present, CD19 and BCMA are the\u00a0most\u00a0common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being\u00a0explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen\u00a0escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients\u00a0relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance\u00a0to\u00a0CAR-T\u00a0cell therapy, and provide\u00a0some\u00a0practical recommendations.<\/jats:p>","DOI":"10.3389\/fimmu.2022.927153","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:57:45Z","timestamp":1654822665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":357,"title":["CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaomin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Follicular Lymphoma: The Phase 2 ELARA Trial","volume":"28","author":"Fowler","year":"2021","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the Safety of CAR-T Cell Therapy by Controlling CRS-Related Coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192203","article-title":"Optimized Gene Engineering of Murine CAR-T Cells Reveals the Beneficial Effects of IL-15 Coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory\/Recurrent Multiple Myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2020-136866","article-title":"Successful 24-Hours Manufacture of Anti-CD19\/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)","volume":"136","author":"Yang","year":"2020","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136866","article-title":"Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0403-2","article-title":"A Retrospective Comparison of Allogenic and Autologous Chimeric Antigen Receptor T Cell Therapy Targeting CD19 in Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"54","author":"Hu","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene Ciloleucel in Relapsed or Refractory Indolent non-Hodgkin Lymphoma (ZUMA-5): A Single-Arm, Multicentre, Phase 2 Trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.145","article-title":"High Efficacy and Safety of Low Dose CD19 Directed CAR-T Cell Therapy in 51 Refractory or Relapsed B Acute Lymphoblastic Leukemia Patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective Response and Delayed Toxicities of Refractory Advanced Diffuse Large B-Cell Lymphoma Treated by CD20-Directed Chimeric Antigen Receptor-Modified T Cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17054","DOI":"10.1038\/sigtrans.2017.54","article-title":"Long-Term Safety and Efficacy of CART-20 Cells in Patients With Refractory or Relapsed B-Cell non-Hodgkin Lymphoma: 5-Years Follow-Up Results of the Phase I and IIa Trials","volume":"2","author":"Zhang","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3259","article-title":"Phase II Trial of Co-Administration of CD19- and CD20-Targeted Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Large B Cell Lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow Cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-Chimeric Antigen Receptors Targeting B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-Cell Therapy in Refractory or Relapsed B Acute Lymphoblastic Leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-Targeted CAR T Cells Induce Remission in B-ALL That is Naive or Resistant to CD19-Targeted CAR Immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S312904","article-title":"Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T Therapy","volume":"14","author":"Zhu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41408-021-00465-9","article-title":"A Novel Full-Human CD22-CAR T Cell Therapy With Potent Activity Against CD22 Low B-ALL","volume":"11","author":"Tan","year":"2021","journal-title":"Blood Cancer J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL Cells by CD7-Targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-Based CRS Management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-In-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107731","article-title":"Chimeric Antigen Receptor T Cells Targeting CD7 in a Child With High-Risk T-Cell Acute Lymphoblastic Leukemia","volume":"96","author":"Xie","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-019-09937-9","article-title":"Characterization of an Anti-CD5 Directed CAR T-Cell Against T-Cell Malignancies","volume":"16","author":"Wada","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-020-10092-9","article-title":"Treatment of Aggressive T Cell Lymphoblastic Lymphoma\/leukemia Using Anti-CD5 CAR T Cells","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical Targeting of Human T-Cell Malignancies Using CD4-Specific Chimeric Antigen Receptor (CAR)-Engineered T Cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-Cells for T-Cell Malignancies: Challenges in Distinguishing Between Therapeutic, Normal, and Neoplastic T-Cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell Receptor \u03b2-Chain Constant Region for Immunotherapy of T Cell Malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13045-021-01178-z","article-title":"CAR T Cells Targeting CD99 as an Approach to Eradicate T-Cell Acute Lymphoblastic Leukemia Without Normal Blood Cells Toxicity","volume":"14","author":"Shi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"blood.2021013648","DOI":"10.1182\/blood.2021013648","article-title":"Anti-CCR9 Chimeric Antigen Receptor T Cells for T Cell Acute Lymphoblastic Leukemia","author":"Maciocia","year":"2022","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab Vedotin With Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-Year Outcomes for Frontline Brentuximab Vedotin With CHP for CD30-Expressing Peripheral T-Cell Lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.231183","article-title":"CD28.OX40 Co-Stimulatory Combination is Associated With Long In Vivo Persistence and High Activity of CAR.CD30 T-Cells","volume":"106","author":"Guercio","year":"2021","journal-title":"Haematologica"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00295-8","article-title":"A New Immunotherapy Strategy Targeted CD30 in Peripheral T-Cell Lymphomas: CAR-Modified T-Cell Therapy Based on CD30 mAb","volume":"29","author":"Wu","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI94306","article-title":"Clinical and Immunological Responses After CD30-Specific Chimeric Antigen Receptor-Redirected Lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0274-9","article-title":"Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for Relapsed\/Refractory CD30+ Lymphoma Patients","volume":"10","author":"Wang","year":"2020","journal-title":"Blood Cancer J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy Metabolic Tumor Volume is Associated With Response to CD30 CAR T Cells in Hodgkin Lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv"},{"key":"B47","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1182\/blood.2021013881","article-title":"Relapsed Classic Hodgkin Lymphoma With Decreased CD30 Expression After Brentuximab and Anti-CD30 CAR-T Therapies","volume":"139","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.03.003","article-title":"Myeloid Precursors and Acute Myeloid Leukemia Cells Express Multiple CD33-Related Siglecs","volume":"34","author":"Nguyen","year":"2006","journal-title":"Exp Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000845","article-title":"41BB-Based and CD28-Based CD123-Redirected T-Cells Ablate Human Normal Hematopoiesis In Vivo","volume":"8","author":"Baroni","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1945804","article-title":"Evaluation of Switch-Mediated Costimulation in Trans on Universal CAR-T Cells (UniCAR) Targeting CD123-Positive AML","volume":"10","author":"Meyer","year":"2021","journal-title":"Oncoimmunology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009759","article-title":"Proof of Concept for a Rapidly Switchable Universal CAR-T Platform With UniCAR-T-CD123 in Relapsed\/Refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T Cells for Treatment of Relapsed\/Refractory Acute Myelogenous Leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"B54","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-Type Lectin-Like Molecule-1: A Novel Myeloid Cell Surface Marker Associated With Acute Myeloid Leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T Cells Targeting CLL-1 as an Approach to Treat Acute Myeloid Leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3892\/mmr.2021.11847","article-title":"Cytotoxic Effect of CLL-1 CAR-T Cell Immunotherapy With PD-1 Silencing on Relapsed\/Refractory Acute Myeloid Leukemia","volume":"23","author":"Lin","year":"2021","journal-title":"Mol Med Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008221","article-title":"CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia Without HSC Toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 With Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Patients Treated With Hypomethylating Agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a Novel Target for CAR T-Cell Therapy in Acute Myeloid Leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","article-title":"CAR-T Cells Targeting a Nucleophosmin Neoepitope Exhibit Potent Specific Activity in Mouse Models of Acute Myeloid Leukaemia","volume":"5","author":"Xie","year":"2021","journal-title":"Nat BioMed Eng"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T Cells With an Off-Switch Exhibit Potent Activity Against AML and Can Be Depleted to Expedite Bone Marrow Recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-Cells Targeting FLT3 Have Potent Activity Against FLT3-ITD+ AML and Act Synergistically With the FLT3-Inhibitor Crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.11.7358","article-title":"Human Flt3 is Expressed at the Hematopoietic Stem Cell and the Granulocyte\/Macrophage Progenitor Stages to Maintain Cell Survival","volume":"180","author":"Kikushige","year":"2008","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-Cell Maturation Antigen (BCMA) in Multiple Myeloma: Rationale for Targeting and Current Therapeutic Approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008936","article-title":"A Phase 1 Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.346","article-title":"A Phase I Study of Anti-BCMA CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma and Plasma Cell Leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755866","article-title":"Anti-BCMA CAR-T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials","volume":"12","author":"Que","year":"2021","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211019622","article-title":"The Role of Idecabtagene Vicleucel in Patients With Heavily Pretreated Refractory Multiple Myeloma","volume":"12","author":"Oriol","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-Cell Therapy for Multiple Myeloma: State of the Art and Prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and Efficacy of Targeting CD138 With a Chimeric Antigen Receptor for the Treatment of Multiple Myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"B76","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-Directed Adoptive Immunotherapy of Chimeric Antigen Receptor (CAR)-Modified T Cells for Multiple Myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"key":"B77","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal Antibodies Targeting CD38 in Hematological Malignancies and Beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-Clinical Evaluation of CD38 Chimeric Antigen Receptor Engineered T Cells for the Treatment of Multiple Myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02214-z","article-title":"High Efficacy and Safety of CD38 and BCMA Bispecific CAR-T in Relapsed or Refractory Multiple Myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A Bispecific CAR-T Cell Therapy Targeting BCMA and CD38 in Relapsed or Refractory Multiple Myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036814","article-title":"Surface Molecule CD229 as a Novel Target for the Diagnosis and Treatment of Multiple Myeloma","volume":"96","author":"Atanackovic","year":"2011","journal-title":"Haematologica"},{"key":"B82","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T Cells Eliminate Multiple Myeloma and Tumor Propagating Cells Without Fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat Commun"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T Cells Eliminate Myeloma and Confer Selective Fratricide of SLAMF7(+) Normal Lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: A First-in-Human Clinical Trial With SLAMF7 CAR-T Cells Prepared by Virus-Free Sleeping Beauty Gene Transfer to Treat Multiple Myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-Based Chimeric Antigen Receptor for Dual Targeting of BCMA and TACI in Multiple Myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational Design of a Trimeric APRIL-Based CAR-Binding Domain Enables Efficient Targeting of Multiple Myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a Target for the Immunotherapy of Multiple Myeloma With Rationally Designed CAR T Cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine Release Syndrome Associated With Chimeric-Antigen Receptor T-Cell Therapy: Clinicopathological Insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2021.0057","article-title":"Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy","volume":"41","author":"Dong","year":"2021","journal-title":"J Interferon Cytokine Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-Derived IL-1 and IL-6 are Differentially Required for Cytokine-Release Syndrome and Neurotoxicity Due to CAR T Cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T Cell-Induced Cytokine Release Syndrome is Mediated by Macrophages and Abated by IL-1 Blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-Center Experience Using Anakinra for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the Cytokine Storm: The Use of Intravenous Anakinra in Haemophagocytic Lymphohistiocytosis or Macrophage Activation Syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical Efficacy of Anakinra to Mitigate CAR T-Cell Therapy-Associated Toxicity in Large B-Cell Lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"B96","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF Inhibition Reduces Cytokine Release Syndrome and Neuroinflammation But Enhances CAR-T Cell Function in Xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC119.007558","article-title":"Granulocyte-Macrophage Colony-Stimulating Factor Inactivation in CAR T-Cells Prevents Monocyte-Dependent Release of Key Cytokine Release Syndrome Mediators","volume":"294","author":"Sachdeva","year":"2019","journal-title":"J Biol Chem"},{"key":"B98","doi-asserted-by":"publisher","first-page":"eaax7969","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-Mediated Target Cell Pyroptosis by CAR T Cells Triggers Cytokine Release Syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-Sensing Receptors in Sterile Inflammation and Inflammatory Diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0228-2","article-title":"The Gasdermins, a Protein Family Executing Cell Death and Inflammation","volume":"20","author":"Broz","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41419-021-03428-x","article-title":"DAMPs Released by Pyroptotic Cells as Major Contributors and Therapeutic Targets for CAR-T-Related Toxicities","volume":"12","author":"Deng","year":"2021","journal-title":"Cell Death Dis"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.04.001","article-title":"Monocyte Lineage-Derived IL-6 Does Not Affect Chimeric Antigen Receptor T-Cell Function","volume":"19","author":"Singh","year":"2017","journal-title":"Cytotherapy"},{"key":"B103","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the Potential Key Mediator in CAR-T Related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular Mechanism and Function of CD40\/CD40L Engagement in the Immune System","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/s0301-472x(02)00921-9","article-title":"CD40L Induces Proliferation, Self-Renewal, Rescue From Apoptosis, and Production of Cytokines by CD40-Expressing AML Blasts","volume":"30","author":"Aldinucci","year":"2002","journal-title":"Exp Hematol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/07357907.2014.988340","article-title":"Co-Expression of CD40\/CD40L on XG1 Multiple Myeloma Cells Promotes IL-6 Autocrine Function","volume":"33","author":"Qi","year":"2015","journal-title":"Cancer Invest"},{"key":"B107","article-title":"CD11a-CD18 and CD102 Interactions Mediate Human Myeloma Cell Growth Arrest Induced by CD40 Stimulation","volume":"56","author":"Pellat-Deceunynck","year":"1996","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.3.1039.003k02_1039_1046","article-title":"CD40 Activation Mediates P53-Dependent Cell Cycle Regulation in Human Multiple Myeloma Cell Lines","volume":"95","author":"Teoh","year":"2000","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular Basis and Therapeutic Implications of CD40\/CD40L Immune Checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","article-title":"CD40 Stimulation as a Molecular Adjuvant for Cancer Vaccines and Other Immunotherapies","volume":"19","author":"Bullock","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.082107699","article-title":"CD40 Stimulation Leads to Effective Therapy of CD40(-) Tumors Through Induction of Strong Systemic Cytotoxic T Lymphocyte Immunity","volume":"99","author":"van Mierlo","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B112","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The Model of Cytokine Release Syndrome in CAR T-Cell Treatment for B-Cell non-Hodgkin Lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity Associated With CD19-Targeted CAR-T Cell Therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1084","article-title":"CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell-Associated Neurotoxicity","volume":"7","author":"Mackall","year":"2017","journal-title":"Cancer Discov"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity After Adoptive Immunotherapy With CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T Cell-Associated Neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated With CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov"},{"key":"B121","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant Cerebral Cytokine Release Syndrome in CD19-Directed Chimeric Antigen Receptor-Modified T Cell Therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20920","article-title":"Blockade of IL-15 Activity Inhibits Microglial Activation Through the NFkappaB, P38, and ERK1\/2 Pathways, Reducing Cytokine and Chemokine Release","volume":"58","author":"Gomez-Nicola","year":"2010","journal-title":"Glia"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/568543","article-title":"Pivotal Roles of GM-CSF in Autoimmunity and Inflammation","volume":"2015","author":"Shiomi","year":"2015","journal-title":"Mediat Inflammation"},{"key":"B124","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4049\/jimmunol.178.1.39","article-title":"GM-CSF Production by Autoreactive T Cells is Required for the Activation of Microglial Cells and the Onset of Experimental Autoimmune Encephalomyelitis","volume":"178","author":"Ponomarev","year":"2007","journal-title":"J Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00757-x","article-title":"The Blood-Brain Barrier in Systemic Infection and Inflammation","volume":"18","author":"Galea","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do Not Influence the Efficacy and Kinetics of CAR-T Cells for B-Cell Acute Lymphoblastic Leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1177\/2040620721989585","article-title":"B-Cell Maturation Antigen (BCMA) in Multiple Myeloma: The New Frontier of Targeted Therapies","volume":"12","author":"Sanchez","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638678","article-title":"Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune Reconstitution and Infectious Complications Following Axicabtagene Ciloleucel Therapy for Large B-Cell Lymphoma","volume":"5","author":"Spiegel","year":"2021","journal-title":"Blood Adv"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485","article-title":"Clinical Development of CAR T Cells-Challenges and Opportunities in Translating Innovative Treatment Concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809158","article-title":"In Vivo Generation of Human CD19-CAR T Cells Results in B-Cell Depletion and Signs of Cytokine Release Syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000862","article-title":"SARS-CoV-2 Infection in Immunocompromised Patients: Humoral Versus Cell-Mediated Immunity","volume":"8","author":"Wei","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious Complications of CD19-Targeted Chimeric Antigen Receptor-Modified T-Cell Immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory Signatures for Quick Diagnosis of Life-Threatening Infection During the CAR T-Cell Therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000927","article-title":"Safety and Efficacy of CAR-T Cell Targeting BCMA in Patients With Multiple Myeloma Coinfected With Chronic Hepatitis B Virus","volume":"8","author":"Han","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B137","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral Infection\/Reactivation During Long-Term Follow-Up in Multiple Myeloma Patients With Anti-BCMA CAR Therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic Recovery and Immune Reconstitution After Axicabtagene Ciloleucel in Patients With Large B-Cell Lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S280535","article-title":"Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1bb-Based CD19-Directed CAR-T Therapy","volume":"13","author":"Yang","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory Trial of a Biepitopic CAR T-Targeting B Cell Maturation Antigen in Relapsed\/Refractory Multiple Myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004000","article-title":"How I Prevent Infections in Patients Receiving CD19-Targeted Chimeric Antigen Receptor T Cells for B-Cell Malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: A Model for CAR T-Cell-Related Hematologic Toxicity in Relapsed\/Refractory Large B-Cell Lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe Cytokine Release Syndrome is Associated With Hematologic Toxicity Following CD19 CAR T-Cell Therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic Recovery in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0610330","article-title":"The CD40\/CD40 Ligand Interactions Exert Pleiotropic Effects on Bone Marrow Granulopoiesis","volume":"89","author":"Mavroudi","year":"2011","journal-title":"J Leukoc Biol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012048","article-title":"HMGB1-Mediated Restriction of EPO Signaling Contributes to Anemia of Inflammation","volume":"139","author":"Dulmovits","year":"2022","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1998.18.555","article-title":"Proinflammatory Cytokines Lowering Erythropoietin Production","volume":"18","author":"Jelkmann","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of Inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N Engl J Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.025","article-title":"Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"26","author":"Schubert","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and Late Hematologic Toxicity Following CD19 CAR-T Cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B153","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/stem.2715","article-title":"Concise Review: Emerging Principles From the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies","volume":"36","author":"Jain","year":"2018","journal-title":"Stem Cells"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002721","article-title":"Thrombopoietin Receptor Agonists for Acquired Thrombocytopenia Following Anti-CD19 CAR-T-Cell Therapy: A Case Report","volume":"9","author":"Baur","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.798352","article-title":"Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy","volume":"11","author":"Xing","year":"2021","journal-title":"Front Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation Disorders After Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients With Relapsed and Refractory Hematologic Malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004716","article-title":"Incidence and Risk Factors Associated With Bleeding and Thrombosis Following Chimeric Antigen Receptor T-Cell Therapy","volume":"5","author":"Johnsrud","year":"2021","journal-title":"Blood Adv"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01226-9","article-title":"CRS-Related Coagulopathy in BCMA Targeted CAR-T Therapy: A Retrospective Analysis in a Phase I\/II Clinical Trial","volume":"56","author":"Shao","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2011","article-title":"Cutting Edge: T Cells Trigger CD40-Dependent Platelet Activation and Granular RANTES Release: A Novel Pathway for Immune Response Amplification","volume":"172","author":"Danese","year":"2004","journal-title":"J Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.20.10.2322","article-title":"Role of Platelet P-Selectin and CD40 Ligand in the Induction of Monocytic Tissue Factor Expression","volume":"20","author":"Lindmark","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007252","article-title":"Platelet Activation and Platelet-Monocyte Aggregate Formation Trigger Tissue Factor Expression in Patients With Severe COVID-19","volume":"136","author":"Hottz","year":"2020","journal-title":"Blood"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/35393","article-title":"CD40 Ligand on Activated Platelets Triggers an Inflammatory Reaction of Endothelial Cells","volume":"391","author":"Henn","year":"1998","journal-title":"Nature"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.2.513.513","article-title":"C-Reactive Protein Induces Human Peripheral Blood Monocytes to Synthesize Tissue Factor","volume":"82","author":"Cermak","year":"1993","journal-title":"Blood"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00825.2009","article-title":"Upregulation of Tissue Factor in Monocytes by Cleaved High Molecular Weight Kininogen is Dependent on TNF-Alpha and IL-1beta","volume":"298","author":"Khan","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.96.2.396","article-title":"Activation of Monocyte\/Macrophage Functions Related to Acute Atheroma Complication by Ligation of CD40: Induction of Collagenase, Stromelysin, and Tissue Factor","volume":"96","author":"Mach","year":"1997","journal-title":"Circulation"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0107","article-title":"Effects of Inflammatory Cytokines on the Release and Cleavage of the Endothelial Cell-Derived Ultralarge Von Willebrand Factor Multimers Under Flow","volume":"104","author":"Bernardo","year":"2004","journal-title":"Blood"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02989.x","article-title":"Inflammatory Cytokines Inhibit ADAMTS13 Synthesis in Hepatic Stellate Cells and Endothelial Cells","volume":"6","author":"Cao","year":"2008","journal-title":"J Thromb Haemost"},{"key":"B168","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12185-020-02992-w","article-title":"Advances in the Diagnosis and Treatment of Disseminated Intravascular Coagulation in Haematological Malignancies","volume":"113","author":"Ikezoe","year":"2021","journal-title":"Int J Hematol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14799","article-title":"Preclinical and Clinical Advances in Dual-Target Chimeric Antigen Receptor Therapy for Hematological Malignancies","volume":"112","author":"Guo","year":"2021","journal-title":"Cancer Sci"},{"key":"B170","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.bbmt.2018.12.148","article-title":"2-Year Follow-Up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Refractory Large B Cell Lymphoma","volume":"25","author":"Neelapu","year":"2019","journal-title":"Biol Blood Marrow Tr"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic Mechanisms of Target Antigen Loss in CAR19 Therapy of Acute Lymphoblastic Leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR Immune Pressure Induces B-Precursor Acute Lymphoblastic Leukaemia Lineage Switch Exposing Inherent Leukaemic Plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"B173","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic Loss of BCMA as a Resistance Mechanism to CAR T Cell Therapy in a Patient With Multiple Myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T Cell Trogocytosis and Cooperative Killing Regulate Tumour Antigen Escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.033","article-title":"A Novel and Efficient Tandem CD19- and CD22-Directed CAR for B Cell ALL","volume":"30","author":"Zanetti","year":"2022","journal-title":"Mol Ther"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005278","article-title":"Optimized Tandem CD19\/CD20 CAR-Engineered T Cells in Refractory\/Relapsed B-Cell Lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Relapsed B Cell Malignancies: A Phase 1 Dose Escalation and Expansion Trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0675","article-title":"CD19\/CD22 Dual-Targeted CAR T-Cell Therapy for Relapsed\/Refractory Aggressive B-Cell Lymphoma: A Safety and Efficacy Study","volume":"9","author":"Wei","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T Cells Targeting Both CD19 and CD22 for Therapy of Adults With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc6401","article-title":"Trispecific CD19-CD20-CD22-Targeting duoCAR-T Cells Eliminate Antigen-Heterogeneous B Cell Tumors in Preclinical Models","volume":"13","author":"Schneider","year":"2021","journal-title":"Sci Transl Med"},{"key":"B182","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF Ligand-Based CAR-T Cell Targeting Three Receptors and Multiple B Cell Cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050","article-title":"Gamma-Secretase Inhibition Increases Efficacy of BCMA-Specific Chimeric Antigen Receptor T Cells in Multiple Myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22892","article-title":"Tumor Cell Recognition by \u03b3\u03b4 T Lymphocytes: T-Cell Receptor vs. NK-Cell Receptors","volume":"2","author":"Correia","year":"2013","journal-title":"Oncoimmunology"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237123","article-title":"The MHC Class Ib Protein ULBP1 is a Nonredundant Determinant of Leukemia\/Lymphoma Susceptibility to Gammadelta T-Cell Cytotoxicity","volume":"115","author":"Lan\u00e7a","year":"2010","journal-title":"Blood"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00984","article-title":"Human \u03b3\u03b4 T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias","volume":"9","author":"Pistoia","year":"2018","journal-title":"Front Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-599423","article-title":"\u03b3\u03b4 T-Cell Reconstitution After HLA-Haploidentical Hematopoietic Transplantation Depleted of TCR-\u03b1\u03b2+\/CD19+ Lymphocytes","volume":"125","author":"Airoldi","year":"2015","journal-title":"Blood"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-752162","article-title":"The Potential Role of \u03b3\u03b4 T Cells After Allogeneic HCT for Leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12254","article-title":"Chimeric Antigen Receptor T Cell Persistence and Memory Cell Formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol Cell Biol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121322","article-title":"4-1BB Enhancement of CAR T Function Requires NF-\u03bab and TRAFs","volume":"3","author":"Li","year":"2018","journal-title":"JCI Insight"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and Optimized CD28 Co-Stimulation Enhances Function of Human Mono-Specific and Bi-Specific Third-Generation CAR T Cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1049","article-title":"Selecting Costimulatory Domains for Chimeric Antigen Receptors: Functional and Clinical Considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In Vivo Fate and Activity of Second- Versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1146\/annurev-immunol-042617-053411","article-title":"CD4 Helper and CD8 Cytotoxic T Cell Differentiation","volume":"36","author":"Taniuchi","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol Ther"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T Cells of Defined CD4+:CD8+ Composition in Adult B Cell ALL Patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0195","article-title":"Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling Through Conjugation to Multiple Tumor Cells","volume":"3","author":"Liadi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-Long Leukaemia Remissions With Persistence of CD4+ CAR T Cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol Ther"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077","article-title":"Remote Control of Therapeutic T Cells Through a Small Molecule-Gated Chimeric Receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg7565","article-title":"An Orthogonal IL-2 and IL-2r\u03b2 System Drives Persistence and Activation of CAR T Cells and Clearance of Bulky Lymphoma","volume":"13","author":"Aspuria","year":"2021","journal-title":"Sci Transl Med"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A Human Orthogonal IL-2 and IL-2r\u03b2 System Enhances CAR T Cell Expansion and Antitumor Activity in a Murine Model of Leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-Switch Chimeric Antigen Receptors Controlled by Lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci Transl Med"},{"key":"B208","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41467-020-20671-6","article-title":"Direct Control of CAR T Cells Through Small Molecule-Regulated Antibodies","volume":"12","author":"Park","year":"2021","journal-title":"Nat Commun"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84813","article-title":"Targeted Antibody-Mediated Depletion of Murine CD19 CAR T Cells Permanently Reverses B Cell Aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J Clin Invest"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 Instruct the Generation of Human Memory Stem T Cells From Naive Precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and Through Activation of the Endogenous Immune System","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.24.021605.090727","article-title":"Diverse Functions of IL-2, IL-15, and IL-7 in Lymphoid Homeostasis","volume":"24","author":"Ma","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive Signaling From an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov"},{"key":"B214","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.immuni.2011.09.017","article-title":"An Interleukin-21-Interleukin-10-STAT3 Pathway is Critical for Functional Maturation of Memory CD8+ T Cells","volume":"35","author":"Cui","year":"2011","journal-title":"Immunity"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143534","article-title":"IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15\/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation","volume":"13","author":"Battram","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric Antigen Receptor T (CAR-T) Cells Expanded With IL-7\/IL-15 Mediate Superior Antitumor Effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T Cell Antitumor Activity by Reducing Mtorc1 Activity and Preserving Their Stem Cell Memory Phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24442","article-title":"IL-21 Modulates Memory and Exhaustion Phenotype of T-Cells in a Fatty Acid Oxidation-Dependent Manner","volume":"9","author":"Loschinski","year":"2018","journal-title":"Oncotarget"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"B220","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-Specific T Lymphocytes With Interleukin-15 and a Suicide Gene to Enhance Their Anti-Lymphoma\/Leukemia Effects and Safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.08.005","article-title":"Inducible Secretion of IL-21 Augments Anti-Tumor Activity of Piggybac-Manufactured Chimeric Antigen Receptor T Cells","volume":"22","author":"\u0160tach","year":"2020","journal-title":"Cytotherapy"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00442-4","article-title":"The Nuclear Export Protein XPO1-From Biology to Targeted Therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: First Global Approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"B225","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3892\/or.2021.8121","article-title":"Combining Selective Inhibitors of Nuclear Export (SINEs) With Chimeric Antigen Receptor (CAR) T Cells for CD19-positive Malignancies","volume":"46","author":"Wang","year":"2021","journal-title":"Oncol Rep"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cell Function Against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide","volume":"1818","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00662-0","article-title":"Subsequent Anti-Myeloma Therapy After Idecabtagene Vicleucel Treatment in Patients With Relapsed\/Refractory Multiple Myeloma: A Single Center Analysis","volume":"12","author":"Parrondo","year":"2022","journal-title":"Blood Cancer J"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16550","article-title":"Selinexor-Based Regimens for the Treatment of Myeloma Refractory to Chimeric Antigen Receptor T Cell Therapy","volume":"189","author":"Chari","year":"2020","journal-title":"Br J Haematol"},{"key":"B229","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide Enhances the Efficacy of Anti-BCMA CAR-T Treatment in Relapsed\/Refractory Multiple Myeloma: A Case Report and Revies of the Literature","volume":"71","author":"Zhao","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and Efficacy of CD19-Targeted CAR T Cells With Concurrent Ibrutinib for CLL After Ibrutinib Failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14915","article-title":"Ibrutinib Improves the Efficacy of Anti-CD19-CAR T-Cell Therapy in Patients With Refractory non-Hodgkin Lymphoma","volume":"112","author":"Liu","year":"2021","journal-title":"Cancer Sci"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14638","article-title":"Synergistic Effect of Ibrutinib and CD19 CAR-T Cells on Raji Cells In Vivo and In Vitro","volume":"111","author":"Liu","year":"2020","journal-title":"Cancer Sci"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T Cells in Combination With Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01787","article-title":"Decitabine-Mediated Epigenetic Reprograming Enhances Anti-Leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells","volume":"11","author":"You","year":"2020","journal-title":"Front Immunol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating Therapy Increases Anti-CD123 CAR T Cell Cytotoxicity Against Acute Myeloid Leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat Commun"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S198567","article-title":"Decitabine Enhances Cytotoxic Effect of T Cells With an Anti-CD19 Chimeric Antigen Receptor in Treatment of Lymphoma","volume":"12","author":"Li","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2188","article-title":"Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells Through Inhibition of Apoptosis","volume":"27","author":"Holthof","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging Therapy Prior to Axicabtagene Ciloleucel for Relapsed\/Refractory Large B-Cell Lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-Targeted CAR T-Cell Therapy Plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.10.004","article-title":"Adoptive T Cell Therapy of Solid Tumors: Time to Team Up With Immunogenic Chemo\/Radiotherapy","volume":"74","author":"Pocaterra","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B244","doi-asserted-by":"publisher","first-page":"EAAG1266","DOI":"10.1126\/sciimmunol.aag1266","article-title":"The Intersection of Radiotherapy and Immunotherapy: Mechanisms and Clinical Implications","volume":"1","author":"Spiotto","year":"2016","journal-title":"Sci Immunol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.166","article-title":"Definitive Chemoradiation Alters the Immunologic Landscape and Immune Checkpoints in Head and Neck Cancer","volume":"115","author":"Sridharan","year":"2016","journal-title":"Br J Cancer"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3MR1116-468R","article-title":"Extracellular Matrix and the Myeloid-in-Myeloma Compartment: Balancing Tolerogenic and Immunogenic Inflammation in the Myeloma Niche","volume":"102","author":"Asimakopoulos","year":"2017","journal-title":"J Leukoc Biol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.764698","article-title":"The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia","volume":"9","author":"Pimenta","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00262","article-title":"A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040988","article-title":"Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance","volume":"12","author":"Holthof","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3140","article-title":"Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment","volume":"28","author":"Autio","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000847","article-title":"The Immune Landscape and Response to Immune Checkpoint Blockade Therapy in Lymphoma","volume":"135","author":"Kline","year":"2020","journal-title":"Blood"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T Cell Anergy, Exhaustion, Senescence, and Stemness in the Tumor Microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B253","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41409-020-01023-w","article-title":"Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: Promise and Challenges","volume":"56","author":"Dhakal","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B254","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/s41409-020-01023-w","article-title":"Immune Checkpoint Inhibitors in Lymphoma: Challenges and Opportunities","volume":"9","author":"Hatic","year":"2021","journal-title":"Ann Transl Med"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061326","article-title":"Understanding Immune Evasion and Therapeutic Targeting Associated With PD-1\/PD-L1 Pathway in Diffuse Large B-Cell Lymphoma","volume":"20","author":"Song","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab are Safe and Effective Against Relapsed\/Refractory B-Cell non-Hodgkin Lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10783","article-title":"CAR-T 19 Combined With Reduced-Dose PD-1 Blockade Therapy for Treatment of Refractory Follicular Lymphoma: A Case Report","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol Lett"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108382","article-title":"Use of CAR-T Cell Therapy, PD-1 Blockade, and Their Combination for the Treatment of Hematological Malignancies","volume":"214","author":"Song","year":"2020","journal-title":"Clin Immunol"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26286","article-title":"Blockade of PD-1 Immunosuppression Boosts CAR T-Cell Therapy","volume":"2","author":"John","year":"2013","journal-title":"Oncoimmunology"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7096","article-title":"Effect and Changes in PD-1 Expression of CD19 CAR-T Cells From T Cells Highly Expressing PD-1 Combined With Reduced-Dose PD-1 Inhibitor","volume":"41","author":"Zhang","year":"2019","journal-title":"Oncol Rep"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195","article-title":"Targeted Delivery of a PD-1-Blocking scFv by CAR-T Cells Enhances Anti-Tumor Efficacy In Vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.11.291","article-title":"Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia","volume":"22","author":"Kenderian","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02895-7","article-title":"Boosting CAR T-Cell Responses in Lymphoma by Simultaneous Targeting of CD40\/4-1BB Using Oncolytic Viral Gene Therapy","volume":"70","author":"Wenthe","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.4161\/21624011","article-title":"Healing After Death: Antitumor Immunity Induced by Oncolytic Adenoviral Therapy","volume":"3","author":"Jiang","year":"2014","journal-title":"Oncoimmunology"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27138","article-title":"Rewiring Cancer Cell Death to Enhance Oncolytic Viro-Immunotherapy","volume":"2","author":"Workenhe","year":"2013","journal-title":"Oncoimmunology"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-020-0176-9","article-title":"Immunostimulatory Oncolytic Virotherapy for Multiple Myeloma Targeting 4-1BB and\/or CD40","volume":"27","author":"Wenthe","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.832645","article-title":"Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-\u03b2","volume":"13","author":"Alabanza","year":"2022","journal-title":"Front Immunol"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2055703","article-title":"Superior Antitumor Immunotherapy Efficacy of Kynureninase Modified CAR-T Cells Through Targeting Kynurenine Metabolism","volume":"11","author":"Yang","year":"2022","journal-title":"Oncoimmunology"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.927153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:57:53Z","timestamp":1654822673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.927153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":270,"alternative-id":["10.3389\/fimmu.2022.927153"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.927153","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"article-number":"927153"}}